+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global CA 125 Test Market Size was valued at USD 0.9 Billion in 2022. The CA 125 Test market industry is projected to grow from USD 0.7 Billion in 2023 to USD 1.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.40% during the forecast period (2023 - 2032). Increased cancer prevalence and increased need for cancer detection and treatment, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report.
Source: Secondary Research, Primary Research, Research Layer Database and Analyst Review
Prevalence of ovarian cancer is anticipated to increase, and the significance of early identification and treatment is anticipated to increase. As of 2018, ovarian cancer had the highest death rate among all gynecologic cancers. It resulted in over 14,000 fatalities in the US in 2018. Bloating, irregular periods, vaginal bleeding, indigestion, and weariness are just a few examples of the condition' generic symptoms. It is more difficult to detect early disease because there aren't any recognisable symptoms.
Due to the fact that the majority of patients only acquire advanced-stage diagnosis, the prognosis for diseases is still grim. Therefore, a thorough understanding of disease biology is essential to developing effective therapeutic options with the goal of decreasing toxicity and overcoming resistance. Additional biomarker studies could aid in determining whether patients need a maintenance plan. An increase in government initiatives and increasing funding for ovarian cancer research are two factors that are predicted to drive the market. For instance, ovarian cancer research and development are the main goals of the non-profit organisation Ovarian Cancer Research Alliance (OCRA). It supports numerous studies aiming at locating and curing this illness.
The World Health Organisation (WHO) reports that five-year breast cancer survival rates are above 90% in high-income nations, compared to 66% in India and 40% in South Africa. Some cancer indicators are found via blood tests known as CA 125 testing, which may aid in the diagnosis of breast cancer. Breast cancer tumour markers can be used for screening, monitoring the course of the disease, identifying recurrence, and monitoring the efficacy of treatment. Therefore, the increasing use of tumour markers for breast cancer is what is driving the growth of the CA 125 test Market throughout the forecast period.
According to the American Cancer Society, there will be 21,750 new cases of ovarian cancer in women in 2020, and 13,940 of those cases will result in death. The market is expected to expand over the course of the projected period as a result of increased ovarian cancer awareness in developed nations, simple accessibility, and reasonably priced test costs. On the other hand, it is projected that the global market would soon be hampered by the low level of awareness of ovarian cancer in developing and undeveloped nations. The high cost of testing equipment restricts industry growth. Surveys show that the Covid-19 outbreak has caused a 90% reduction in the number of diagnostic facilities. The number of patients entering hospitals and clinics has fallen due to the increased risk of infection, which has resulted in a decline in the rates of diagnosis and treatment. It is projected that the growth of the CA 125 Test Market during the projection period would be adversely affected in the short term by labour shortages and transportation problems affecting the global business community. Thus, driving the CA 125 Test market revenue.
The global CA 125 Test market segmentation, based on Device & Accessory, includes Spectrometer, Analyzer, Sample Collection Tubes, Otopic Labelled Peptides, and Others. Spectrometer segment dominated the global market in 2022. In spectrometry, reactions, radiation strength and wavelength measurements, and interactions between light and matter are all studied. The mass spectrometry technology is used in clinical mass spectrometry for diagnostic purposes. Clinical mass spectrometry is used in medical labs to do toxicological testing, identify metabolic problems, and find the presence of biomarkers or enzymes.
The global CA 125 Test market segmentation, based on Indication, includes Cancer, Uterine Fibroids, Endometriosis, Liver Disease, and Others. Cancer segment dominated the global market in 2022. Uterine fibroids, also known as leiomyomas or myomas, do not increase the risk of uterine cancer, and they seldom progress to cancer. The tissue that normally surrounds the uterus starts to protrude outside of it in endometriosis. At the end of the cycle, this tissue degrades and bleeds, much like uterine tissue does during your period. However, this blood has nowhere to go. The nearby tissues could swell or itch.
The global CA 125 Test market segmentation, based on End User, includes Hospital & Clinic and Diagnostic Center. Diagnostic center segment dominated the global CA 125 Test market in 2022. A clinic might be more likely to offer emergency care after hours, whereas diagnostic centres might prefer to keep regular hours. It's feasible that a clinic will offer therapy at a lower cost.
Download Free Sample to learn more about this report.
Source: Secondary Research, Primary Research, Research Layer Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America CA 125 Test Market dominated this market in 2022 (45.80%). This is due to the fact that gynecologic diagnostics have been successful commercially in the US. Favourable government measures, an increase in healthcare spending, and the existence of significant manufacturers are further factors supporting the market in this area. Further, the U.S. CA 125 Test market held the largest market share, and the Canada CA 125 Test market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, Research Layer Database and Analyst Review
Europe CA 125 Test market accounted for the healthy market share in 2022. One of the elements influencing the growth of this region is the increase in the number of new cancer cases in Europe. Further, the German CA 125 Test market held the largest market share, and the U.K CA 125 Test market was the fastest growing market in the European region.
The Asia Pacific CA 125 Test market is expected to register significant growth from 2023 to 2032. This is due to factors like the overall expansion of the economy, improved healthcare facilities, greater disposable income, and raised consumer awareness. During the projected period, it is anticipated that developing countries like China, India, and South Korea would have significant growth in the ovarian cancer diagnostics market. Moreover, China’s CA 125 Test market held the largest market share and the Indian CA 125 Test market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the CA 125 Test market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, CA 125 Test industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global CA 125 Test industry to benefit clients and increase the market sector. In recent years, the CA 125 Test industry has offered some of the most significant advantages to medicine. Major players in the CA 125 Test market, including Allergan plc., Amgen Inc., Bayer, BD, Eli Lilly Company, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceuticals Private Limited, AMAG Pharmaceuticals, Johnson & Johnson, Sanofi, Novartis, AbbVie Inc., and GlaxoSmithKline plc., are attempting to increase market demand by investing in research and development Device & Accessorys.
Foundation Medicine develops and produces comprehensive genetic profiling technologies with the aim of supporting physicians in improving treatment choices. In order to identify clinically relevant changes in the tumour genome and potentially broaden the spectrum of treatment options available to patients, the business offers a full genomic profile assessment of the tumour genome. Foundation Medicine's FoundationOne CDx, a comprehensive genomic profiling test, was announced by the business as having obtained FDA approval when LYNPARZA (olaparib) was first-line maintenance therapy for BRCA-mutated metastatic ovarian cancer. This test can detect germline and somatic BRCA1/2 mutations.
Becton Dickinson and Co. (BD) is a producer and supplier of instruments, reagents, and medical equipment. The company's primary products include syringes and pen needles, intravenous catheters, infusion pumps, disposables, automated medication dispensing and supply management systems, pre-fillable drug delivery systems, respiratory ventilation and diagnostic equipment and consumables, items for the secure collection and transportation of diagnostic specimens, instruments and reagent systems to detect a variety of infectious diseases and cancers, and clinical research tools. The general public, hospitals, clinics, the pharmaceutical industry, and researchers in the field of life sciences can all profit from BD's goods. The company markets its products not just in Asia-Pacific but also in the Americas, Europe, the Middle East, and Africa. New Jersey is home to BD's American headquarters. In February 2022, Becton, Dickinson and Company announced that it would purchase Cytognos. The details of the deal were kept under wraps. With the acquisition, Becton now has exclusive access to assays licenced from the EuroFlow Consortium.
· Allergan plc.
· Amgen Inc.
· Bayer
· BD
· Eli Lilly Company
· Merck & Co., Inc.
· Pfizer Inc.
· Teva Pharmaceuticals Private Limited
· AMAG Pharmaceuticals
· Johnson & Johnson
· Sanofi
· Novartis
· AbbVie Inc.
· GlaxoSmithKline plc.
July 2021: Tepha, Inc. was bought, according to Becton, Dickinson and Company. The leading producer and creator of specific resorbable polymer technology is Tepha Inc. This acquisition promotes improvements in soft tissue repair and regeneration.
December 2020: The LGC Maine Standards have released the VALIDATE® Tumour Markers. The clinical laboratories' requirements for linearity and calibration verification were met by doing this. These labs employ the Abbott Architect and Abbott Affinity systems.
· Spectrometer
· Analyzer
· Sample Collection Tubes
· Otopic Labelled Peptides
· Others
· Cancer
· Uterine Fibroids
· Endometriosis
· Liver Disease
· Others
· Hospital & Clinic
· Diagnostic Center
· North America
- U.S.
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
| Report Attribute/Metric | Details |
|---|---|
| Market Size 2022 | USD 0.9 Billion |
| Market Size 2023 | USD 0.7 Billion |
| Market Size 2032 | USD 1.7 Billion |
| Compound Annual Growth Rate (CAGR) | 5.40% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2019- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Device & Accessory, Indication, End User, and Region |
| Geographies Covered | Europe, North America, Asia-Pacific, Middle East & Africa, and South America |
| Countries Covered | The U.S, Germany, Canada, U.K., Italy, France, Spain, Japan, China, Australia, India, South Korea, and Brazil |
| Key Companies Profiled | Allergan plc., Amgen Inc., Bayer, BD, Eli Lilly Company, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceuticals Private Limited, AMAG Pharmaceuticals, Johnson & Johnson, Sanofi, Novartis, AbbVie Inc., and GlaxoSmithKline plc |
| Key Market Opportunities | Increasing emphasis on women healthcare |
| Key Market Dynamics | Increasing demand for cancer diagnosis and treatment and rising prevalence of cancer |
The global CA 125 Test Market was valued at USD 0.9 billion in 2022, and it is estimated to reach USD 1.7 billion by 2032.
The global market is projected to grow at a CAGR of 5.40% during the forecast period, 2023-2032
North America had the largest share in the global market
The key players in the market are Allergan plc., Amgen Inc., Bayer, BD, Eli Lilly Company, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceuticals Private Limited, AMAG Pharmaceuticals, Johnson & Johnson, Sanofi, Novartis, AbbVie Inc., and GlaxoSmithKline plc
The Spectrometer Device & Accessory dominated the market in 2022
The Cancer Indication had the largest share in the global market.
Report Code :
RL6541
Published on :
Aug 2023
Request a Free Sample Report
Speak to Analyst